John Ostrominski, MD, MPH: key facts
- Kind of voice
- Academic
- Role
- Brigham and Women's Hospital and Harvard Medical School in Boston
- Quoted on
- Heart disease & stroke
- Press citations held
- 1
- Most recently quoted
- 29 Sept 2026
“This is an important message of reassurance. Despite high risks of adverse health outcomes, persons with frailty are often undertreated due to concerns around potentially attenuated benefits or excess safety risks. This analysis suggests that the benefit/risk balance may be favorable for semaglutide, even in persons with frailty.”
Where John Ostrominski, MD, MPH has been quoted
- Wegovy Benefits Heart Disease Patients Regardless of Frailtymedpagetoday.com · 29 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 29 Sept 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.